Petros Pharmaceuticals plans to expand OTC access for prescription drugs, including ED therapy, targeting a projected $66.5B Rx-to-OTC market by 2033.
Petros Pharmaceuticals Inc (PTPI) aims to expand access of key prescription pharmaceuticals as over-the-counter (OTC) treatment options, targeting the Rx-to-OTC self-care market. According to FMI's Rx-to-OTC Switches Market, the Rx-to-OTC switch market is projected to reach $66.5 billion by 2033, and the company's president, Fady Boctor, stated that the prescription erectile dysfunction market could triple if an ED therapy is made available OTC.
June 17, 2024
3 Articles